KEYUR PRAVINCHANDRA PATEL to Lymphoma, Mantle-Cell
This is a "connection" page, showing publications KEYUR PRAVINCHANDRA PATEL has written about Lymphoma, Mantle-Cell.
Connection Strength
0.546
-
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
Score: 0.131
-
From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Ann Diagn Pathol. 2021 Feb; 50:151649.
Score: 0.120
-
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 03 24; 4(6):1038-1050.
Score: 0.115
-
TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019 Aug; 41:38-42.
Score: 0.109
-
Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):606-9.
Score: 0.072